Wegovy and Finasteride Interaction: What Patients and Clinicians Need to Know

Semaglutide 2.4 mg, marketed as Wegovy, is a once-weekly injectable GLP-1 receptor agonist approved for chronic weight management. Finasteride is an oral 5-alpha reductase inhibitor sold as Proscar (5 mg, for benign prostatic hyperplasia) and Propecia (1 mg, for androgenetic alopecia). These two drugs belong to entirely different classes and are commonly prescribed together in men who are losing weight with a GLP-1 agent while also being treated for hair loss or an enlarged prostate.

The direct answer

There is no known contraindication, dose adjustment, or FDA-labeled warning for combining Wegovy and finasteride. The two drugs are metabolized through different pathways and neither drug's label lists the other as an interacting agent. That does not mean the combination has been formally studied together; it means the mechanisms of each drug do not obviously conflict. Clinicians and patients should still expect periodic monitoring of testosterone-related endpoints during active weight loss, for reasons explained below.

How each drug is cleared from the body

Semaglutide is a large peptide molecule. It is degraded through sequential proteolytic cleavage of the peptide backbone, not through hepatic cytochrome P450 (CYP) enzymes or P-glycoprotein transport. Because it does not depend on CYP metabolism for its own clearance, it has no mechanism to inhibit or induce the CYP enzymes that clear other drugs. This is stated in the FDA-approved prescribing information for Wegovy.

Finasteride is metabolized primarily by CYP3A4 into inactive metabolites that are eliminated in bile and urine. Because semaglutide has no CYP3A4 activity, it cannot meaningfully raise or lower finasteride blood levels. The Proscar prescribing information does not list GLP-1 receptor agonists as interacting agents.

One label-level caveat applies to any oral drug taken around the time of a semaglutide injection: semaglutide slows gastric emptying, which can delay the rate of absorption of co-administered oral medications, particularly during the first weeks of treatment or after a dose increase. The Wegovy label flags this as a general consideration for orally administered drugs with a narrow therapeutic index. Finasteride does not have a narrow therapeutic index, and its absorption is not confined to the stomach, so a modest delay in gastric emptying is unlikely to meaningfully change how much drug the body ultimately absorbs, even if the timing of peak concentration shifts slightly.

The pharmacodynamic question that actually matters

Semaglutide does not act on the androgen receptor or on 5-alpha reductase, the enzyme finasteride blocks. The connection between the two drugs runs through weight loss itself.

Adipose tissue converts testosterone to estradiol through the enzyme aromatase, and men with obesity are recognized in the endocrinology literature to have, on average, lower total and free testosterone than lean men of similar age. Losing a substantial amount of body weight is associated with a rise in testosterone in many of these men, largely attributed to reduced aromatase activity as fat mass decreases. This pattern has been described in the endocrinology and urology literature for years and is reflected in guideline discussions of obesity-related hypogonadism, including the Endocrine Society's clinical practice guideline on obesity pharmacotherapy, which addresses hormonal effects of weight loss in general terms.

Semaglutide's pivotal trial, STEP-1, showed that the 2.4 mg dose produced substantially greater weight loss than placebo over 68 weeks, on the order of an additional 10 to 15 percentage points of body weight lost. That magnitude of weight change is large enough, based on the broader obesity literature, to plausibly shift sex hormone levels in men. The exact figures reported for sex hormone changes within STEP-1 itself should be confirmed against the primary trial publication before being cited precisely in patient materials; we are not reproducing exact numbers here because they could not be verified against a checked source for this article.

If testosterone rises as weight decreases, the pool of substrate available for conversion to dihydrotestosterone (DHT) increases, even while finasteride partially blocks the enzyme that performs that conversion. Two outcomes are plausible: DHT could stay essentially stable if the enzyme blockade fully offsets the added substrate, or DHT could creep upward if the substrate increase outpaces the blockade. No published trial has measured this specific combination prospectively, so which outcome is more common in practice is not established.

Evidence boundary: what is known, what is plausible, what is not established

Established. Semaglutide and finasteride use non-overlapping metabolic pathways, and neither FDA label lists the other as a contraindicated or dose-adjusted combination. Weight loss in general is associated with changes in sex hormone levels in men with obesity.

Plausible but unproven. That semaglutide-driven weight loss could measurably raise testosterone in a given patient enough to partially offset finasteride's DHT-lowering effect, and that this could show up clinically as increased hair shedding or reduced BPH symptom control in some individuals.

Not established. The frequency, magnitude, or clinical significance of any testosterone-mediated interaction between semaglutide and finasteride specifically. No trial has enrolled patients on both drugs to test this question directly, and none of the numeric claims sometimes circulated online (specific nmol/L increases, specific percentage risks of hair shedding, specific DHT thresholds) are attached to a verified study of this exact drug pair.

What the FDA labels say about co-administration

Neither the Wegovy label nor the Proscar label nor the Propecia label identifies the other drug as a contraindication or a required dose adjustment. This absence is consistent with the mechanistic picture above rather than proof that the combination has been formally tested. The FDA's general guidance on CYP substrates, inhibitors, and inducers classifies finasteride as sensitive to strong CYP3A4 inhibitors, but semaglutide is not a CYP3A4 inhibitor, so that sensitivity is not relevant here.

Finasteride is not approved for use in women and is contraindicated during pregnancy because of the risk of fetal harm to a male fetus; that contraindication is unrelated to semaglutide and applies regardless of GLP-1 use.

Wegovy's other clinically meaningful interactions, for context

Finasteride is a low-concern pairing precisely because it does not fall into the categories below, which represent the interactions clinicians actually need to manage with semaglutide:

• Sulfonylureas and insulin. Semaglutide augments glucose-dependent insulin secretion. Combined with a sulfonylurea or insulin, hypoglycemia risk increases, and dose reduction of the other agent is often needed. This is addressed in the American Diabetes Association's Standards of Care.
• Oral contraceptives. Delayed gastric emptying may slow OCP absorption; the Wegovy label recommends an additional or alternative contraceptive method around treatment initiation and dose escalation.
• Warfarin. No direct pharmacokinetic interaction is described, but rapid weight change can alter drug distribution and may prompt more frequent INR checks.

Evidence-status interaction assessment: Wegovy plus finasteride

Practical guidance for patients and prescribers

Timing. There is no requirement to separate finasteride from a Wegovy injection. If a patient happens to take finasteride within about 30 minutes of the weekly injection and wants to minimize any theoretical absorption delay during the first two months of treatment, shifting the oral dose by a couple of hours is a reasonable, low-cost precaution rather than a clinical necessity.

Hormone monitoring. For men using finasteride for androgenetic alopecia who are starting semaglutide for weight management, a baseline testosterone (and DHT, if available and if hair loss is the primary concern) before starting semaglutide, with a repeat at three to six months, is a reasonable monitoring approach if substantial weight loss is expected. This is a judgment call based on physiology, not a guideline requirement specific to this drug pair.

PSA interpretation. Finasteride is known to lower measured PSA values in men treated for BPH, which is why clinicians typically apply a correction factor when interpreting PSA results in men on finasteride. This correction is a property of finasteride itself and is not changed by concurrent semaglutide use or by weight loss.

New or worsening hair shedding. Rapid weight loss from any cause, including GLP-1 therapy, can trigger telogen effluvium, a temporary shedding phase distinct from androgenetic alopecia. Finasteride does not prevent or treat telogen effluvium because that process is not driven by DHT. If shedding appears after starting semaglutide and persists beyond several months, or if the pattern looks like typical male- or female-pattern hair loss rather than diffuse shedding, that warrants a clinical reassessment rather than an assumption that finasteride has stopped working.

When to seek prompt care. Significant new urinary retention symptoms in a man on finasteride for BPH, or rapid or unexplained hormonal symptoms such as new breast tissue changes, are reasons to contact a clinician rather than wait for a routine follow-up, regardless of what is driving them.

Special populations

Men with obesity-related low testosterone who also use finasteride for hair loss. This is a common real-world combination: obesity lowers testosterone, hair loss prompts finasteride, and semaglutide is added for weight management. As weight drops and testosterone potentially rises, the theoretical expectation is that finasteride's effect on hair preservation should remain stable or possibly improve slightly, since more circulating testosterone can still support the hair follicle even while DHT conversion is partly blocked. This is a plausible extrapolation from separate lines of evidence, not a tested clinical finding for this specific pairing.

Older men on finasteride 5 mg for BPH. Weight loss can also reduce visceral fat and abdominal pressure, which may independently improve voiding symptoms. Any change in urinary symptoms after significant weight loss in this group should be evaluated on its own merits rather than assumed to be a drug interaction.

Off-label finasteride use in postmenopausal women. Some clinicians prescribe finasteride off-label for female-pattern hair loss in postmenopausal women. If such a patient is also using semaglutide for weight management, the same general reasoning about weight-related androgen shifts applies, but the evidence base for this population is thinner than for men, and hormonal monitoring should be individualized with the prescribing clinician.

Key takeaways for prescribers

No dose adjustment to semaglutide or finasteride is indicated based on current FDA labeling or known metabolic pathways. The practical clinical task is recognizing that significant weight loss is a physiologic event with its own hormonal consequences, separate from any drug-drug interaction, and building a modest monitoring plan around that fact rather than around a presumed pharmacokinetic conflict that the evidence does not support.